With this notice, Frontiers states its awareness of serious complaints regarding this article. This expression of concern has been posted while Frontiers investigates the allegations. The situation will be updated as soon as the investigation is complete.
Summary
Keywords
proxalutamide, COVID-19, androgen receptor, Antiandrogens, Androgenetic Alopecia, Anti-androgen therapy, Transmembrane protease serine 2, tmprss2
Citation
Frontiers Editorial Office (2022) Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 8:831449. doi: 10.3389/fmed.2021.831449
Received
08 December 2021
Accepted
13 December 2021
Published
17 January 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
8 - 2021
Updates
Copyright
© 2022 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office editorial.office@frontiersin.org
This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.